Table 2.
Clinical and pathological characteristics divided by DFS-INPS.
| Variables | n = 249 (%) | DFS − INPS ≤ 0.4896 | DFS − INPS > 0.4896 | P |
|---|---|---|---|---|
| n = 193 (%) | n = 56 (%) | |||
| Age (median (IQR)) | 49.00 (42.00-57.00) | 49.00 (42.00-57.00) | 47.50 (42.00-57.00) | 0.904 |
| Age | ||||
| ≤ 49 | 132 (53.0) | 102 (52.8) | 30 (53.6) | 1 |
| > 49 | 117 (47.0) | 91 (47.2) | 26 (46.4) | |
| Position | ||||
| Left | 140 (56.2) | 110 (57.0) | 30 (53.6) | 0.763 |
| Right | 109 (43.8) | 83 (43.0) | 26 (46.4) | |
| Menopause | ||||
| 0 | 137 (55.0) | 102 (52.8) | 35 (62.5) | 0.26 |
| 1 | 112 (45.0) | 91 (47.2) | 21 (37.5) | |
| Parturition | ||||
| 0 | 31 (12.4) | 21 (10.9) | 10 (17.9) | 0.219 |
| 1 | 156 (62.7) | 126 (65.3) | 30 (53.6) | |
| ≥ 2 | 62 (24.9) | 46 (23.8) | 16 (28.6) | |
| Clinical T stage | ||||
| 1 | 22 (8.8) | 17 (8.8) | 5 (8.9) | 0.026 |
| 2 | 175 (70.3) | 142 (73.6) | 33 (58.9) | |
| 3 | 48 (19.3) | 33 (17.1) | 15 (26.8) | |
| 4 | 4 (1.6) | 1 (0.5) | 3 (5.4) | |
| Clinical N stage | ||||
| 0 | 8 (3.2) | 6 (3.1) | 2 (3.6) | 0.715 |
| 1 | 28 (11.2) | 23 (11.9) | 5 (8.9) | |
| 2 | 153 (61.4) | 115 (59.6) | 38 (67.9) | |
| 3 | 60 (24.1) | 49 (25.4) | 11 (19.6) | |
| Clinical TNM stage | ||||
| II | 32 (12.9) | 27 (14.0) | 5 (8.9) | 0.442 |
| III | 217 (87.1) | 166 (86.0) | 51 (91.1) | |
| Molecular subtype | ||||
| Luminal A | 39 (15.7) | 34 (17.6) | 5 (8.9) | 0.165 |
| Luminal B | 117 (47.0) | 86 (44.6) | 31 (55.4) | |
| HER-2 OE | 50 (20.1) | 42 (21.8) | 8 (14.3) | |
| TNBC | 43 (17.3) | 31 (16.1) | 12 (21.4) | |
| ER | ||||
| Negative | 98 (39.4) | 77 (39.9) | 21 (37.5) | 0.867 |
| Positive | 151 (60.6) | 116 (60.1) | 35 (62.5) | |
| PR | ||||
| Negative | 123 (49.4) | 98 (50.8) | 25 (44.6) | 0.511 |
| Positive | 126 (50.6) | 95 (49.2) | 31 (55.4) | |
| HER-2 | ||||
| Negative | 99 (39.8) | 83 (43.0) | 16 (28.6) | 0.045 |
| Low expression | 75 (30.1) | 51 (26.4) | 24 (42.9) | |
| Positive | 75 (30.1) | 59 (30.6) | 16 (28.6) | |
| Ki-67 | ||||
| <20% | 107 (43.0) | 93 (48.2) | 14 (25.0) | 0.003 |
| ≥ 20% | 142 (57.0) | 100 (51.8) | 42 (75.0) | |
| P53 | ||||
| Negative | 182 (73.1) | 148 (76.7) | 34 (60.7) | 0.028 |
| Positive | 67 (26.9) | 45 (23.3) | 22 (39.3) | |
| Cycle | ||||
| ≤ 4 | 148 (59.4) | 117 (60.6) | 31 (55.4) | 0.581 |
| >4 | 101 (40.6) | 76 (39.4) | 25 (44.6) | |
| L (median (IQR)) | 1.92 (1.60-2.45) | 2.13 (1.75-2.61) | 1.53 (1.36-1.83) | <0.001 |
| N (median (IQR)) | 3.78 (3.00-4.73) | 3.42 (2.86-4.22) | 5.03 (4.42-6.22) | <0.001 |
| M (median (IQR)) | 0.41 (0.34-0.52) | 0.38 (0.31-0.47) | 0.50 (0.41-0.58) | <0.001 |
| HB (median (IQR)) | 135.0(128.3-141.0) | 135.0(129.2-140.0) | 133.5(126.1-142.3) | 0.532 |
| P (median (IQR)) | 239.0 (210-283) | 238.0(210-278) | 256.5(211-299) | 0.293 |
| ALB (median (IQR)) | 45.00 (43.00-46.50) | 45.00 (43.00-46.30) | 45.00 (43.00-46.78) | 0.895 |
| GLOB (median (IQR)) | 30.00 (27.60-33.00) | 30.00 (27.30-33.00) | 30.00(28.0-33.12) | 0.621 |
| BMI (median (IQR)) | 24.00 (21.80-26.70) | 24.0 (21.60-26.60) | 23.9(22.08-27.55) | 0.242 |
| PNI (median (IQR)) | 55.10 (52.30-57.50) | 55.50 (52.90-58.10) | 52.55(50.6-55.12) | <0.001 |
| AGR (median (IQR)) | 1.48 (1.35-1.64) | 1.50 (1.38-1.64) | 1.46(1.33-1.61) | 0.444 |
| NLR (median (IQR)) | 1.87 (1.45-2.47) | 1.66 (1.37-2.03) | 3.20(2.75-3.64) | <0.001 |
| PLR (median (IQR)) | 120.00(98-150) | 113 (95-136) | 162(130-206) | <0.001 |
| MLR (median (IQR)) | 0.20 (0.16-0.27) | 0.19 (0.15-0.22) | 0.32(0.27-0.37) | <0.001 |
| SII (median (IQR)) | 441 (329-630) | 397 (299-509) | 813(682-1001) | <0.001 |
| SIRI (median (IQR)) | 0.77 (0.51-1.14) | 0.64 (0.48-0.86) | 1.52(1.36-2.08) | <0.001 |
Abbreviations: INPS, inflammation and nutrition prognostic score; IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; HER-2 OE, HER-2 overexpression; L, lymphocyte; N, neutrophil; M, monocyte; Hb, hemoglobin; P, platelet; ALB, albumin; GLOB, globulin; BMI, body mass index; PNI, prognostic nutritional index; AGR, albumin-globulin ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; MLR, monocyte-lymphocyte ratio; SII, systemic immune inflammation index; SIRI, systemic inflammation response index.